Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Atherosclerosis Research

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) is known for its role in cholesterol metabolism.
• Emerging evidence suggests PCSK9 may exert extra-hepatic effects influencing vascular health.
• The specific role of PCSK9 in macrophage cholesterol homeostasis, particularly in ATP binding cassette transporter A1 (Abca1)-mediated cholesterol efflux, requires investigation.

Purpose of the Study:

• To investigate the direct role of PCSK9 in regulating Abca1-mediated cholesterol efflux in macrophages.
• To determine if PCSK9 influences the expression of Abca1 in response to cholesterol loading stimuli.
• To explore the implications of PCSK9's extra-hepatic actions on atherogenesis.

Main Methods:

• Utilized mouse peritoneal macrophages (MPM) from wild-type (WT) and LDL receptor knock-out (Ldlr-/-) mice.
• Assessed Abca1-mediated cholesterol efflux using a radioisotopic technique.
• Quantified Abca1 gene and protein expression via quantitative real-time PCR and Western blot, respectively.

Main Results:

• PCSK9 significantly inhibited Abca1-mediated cholesterol efflux induced by LXR/RXR agonists in WT macrophages (-55%, p < 0.05).
• This inhibition was linked to reduced Abca1 protein and gene expression in WT cells, and downregulated Abca1 gene expression in Ldlr-/- macrophages.
• PCSK9's inhibitory effect was confirmed in acetylated LDL-stimulated macrophages and did not significantly affect other lipid transporters like Sr-b1 and Abcg1.

Conclusions:

• PCSK9 directly downregulates Abca1 gene and protein expression, thereby inhibiting Abca1-mediated cholesterol efflux in macrophages.
• This extra-hepatic action of PCSK9 on macrophage cholesterol efflux may play a significant role in the pathogenesis of atherosclerosis, including foam cell formation.